Biomarkers of respiratory syncytial virus (RSV) infection: Specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity

Paediatric Respiratory Reviews

Volumn 16, Issue 4, 2015, Pages 232-240

  Brown, Paul M ^a   Schneeberger, Dana L ^a   Piedimonte, Giovanni ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Asthma; Brain derived growth factor (BDNF); Bronchiolitis; Lung development; Nerve growth factor (NGF)

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE C4; LEUKOTRIENE E4; NERVE GROWTH FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; PEPTIDOLEUKOTRIENE; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASOPRESSIN; VIRUS RNA; LEUKOTRIENE;

ASTHMA; BRONCHIOLITIS; CHILD HEALTH; DISEASE SEVERITY; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY RATE; NEUTROPHIL; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; IMMUNOLOGY; INFANT; METABOLISM; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX;

ASTHMA; BIOMARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; BRONCHIOLITIS; CHILD, PRESCHOOL; CYTOKINES; HUMANS; INFANT; LEUKOTRIENES; NERVE GROWTH FACTOR; NEUTROPHILS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SEVERITY OF ILLNESS INDEX;

EID: 84930708128     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2015.05.005     Document Type: Review

References (158)

1. Shay D.K., et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. Jama-Journal of the American Medical Association 1999, 282(15):1440-1446.
2. Wright M., Piedimonte G. Respiratory syncytial virus prevention and therapy: past, present, and future. Pediatr Pulmonol 2011, 46(4):324-347.
3. American Academy of Pediatrics Subcommittee on, D. and B. Management of Diagnosis and management of bronchiolitis. Pediatrics, 2006. 118(4): p. 1774-93.
4. Zorc J.J., Hall C.B. Bronchiolitis: recent evidence on diagnosis and management. Pediatrics 2010, 125(2):342-349.
5. Sala K.A., et al. Factors associated with disease severity in children with bronchiolitis. J Asthma 2014, 1-5.
6. Sims D.G., et al. Study of 8-year-old children with a history of respiratory syncytial virus bronchiolitis in infancy. Br Med J 1978, 1(6104):11-14.
7. Mok J.Y., Simpson H. Outcome for acute bronchitis, bronchiolitis, and pneumonia in infancy. Arch Dis Child 1984, 59(4):306-309.
8. Murray M., et al. Respiratory status and allergy after bronchiolitis. Arch Dis Child 1992, 67(4):482-487.
9. Noble V., et al. Respiratory status and allergy nine to 10 years after acute bronchiolitis. Arch Dis Child 1997, 76(4):315-319.
10. Stein R.T., et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999, 354(9178):541-545.
11. Sigurs N., et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000, 161(5):1501-1507.
12. Piedimonte G., Walton C., Samsell L. Vertical transmission of respiratory syncytial virus modulates pre- and postnatal innervation and reactivity of rat airways. PLoS One 2013, 8(4):pe61309.
13. Tortorolo L., et al. Neurotrophin overexpression in lower airways of infants with respiratory syncytial virus infection. Am J Respir Crit Care Med 2005, 172(2):233-237.
14. Hu C., et al. Nerve growth factor and nerve growth factor receptors in respiratory syncytial virus-infected lungs. Am J Physiol Lung Cell Mol Physiol 2002, 283(2):L494-L502.
15. Othumpangat S., et al. NGF is an essential survival factor for bronchial epithelial cells during respiratory syncytial virus infection. PLoS One 2009, 4(7):pe6444.
16. Othumpangat S., Walton C., Piedimonte G. MicroRNA-221 modulates RSV replication in human bronchial epithelium by targeting NGF expression. PLoS One 2012, 7(1):pe30030.
17. Espinoza J.A., et al. Modulation of host adaptive immunity by hRSV proteins. Virulence 2014, 5(7).
18. Chanock R., Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA) II. Epidemiologic aspects of infection in infants and young children. American Journal of Hygiene 1957, 66(3):291-300.
19. Chanock R., Roizman B., Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA) I. Isolation, properties and characterization. American Journal of Hygiene 1957, 66(3):281-290.
20. Murata Y. Respiratory syncytial virus vaccine development. Clin Lab Med 2009, 29(4):725-739.
21. Luo G., et al. A systematic review of predictive modeling for bronchiolitis. Int J Med Inform 2014, 83(10):691-714.
22. Milner M.E., de la Monte S.M., Hutchins G.M. Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndrome. Am J Dis Child 1985, 139(11):1111-1114.
23. Hall C.B., et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986, 315(2):77-81.
24. Navas L., et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992, 121(3):348-354.
25. King J.C., et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr Infect Dis J 1993, 12(9):733-739.
26. Wang E.E., et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr, 1996, 129(3):390-395.
27. Boyce T.G., et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000, 137(6):865-870.
28. Walsh E.E., Peterson D.R., Falsey A.R. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 2004, 189(2):233-238.
29. Hall C.B., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360(6):588-598.
30. Brooks A.M., et al. Predicting deterioration in previously healthy infants hospitalized with respiratory syncytial virus infection. Pediatrics 1999, 104(3 Pt 1):463-467.
31. Hall C.B., Douglas R.G., Geiman J.M. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis 1980, 141(1):98-102.
32. Hall C.B., Douglas R.G. Modes of transmission of respiratory syncytial virus. J Pediatr 1981, 99(1):100-103.
33. Hall C.B., et al. Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun 1981, 33(3):779-783.
34. Hall C.B. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001, 344(25):1917-1928.
35. Englund J.A., et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 1988, 109(3):203-208.
36. Chandwani S., et al. Respiratory syncytial virus infection in human immunodeficiency virus-infected children. J Pediatr 1990, 117(2 Pt 1):251-254.
37. Kim H.W., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89(4):422-434.
38. Chin J., et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969, 89(4):449-463.
39. Carbonell-Estrany X., et al. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. Eur J Clin Microbiol Infect Dis 2008, 27(10):891-899.
40. Hussman J.M., et al. A review of cost-effectiveness of palivizumab for respiratory syncytial virus. Expert Rev Pharmacoecon Outcomes Res 2012, 12(5):553-567.
41. Hussman J.M., Lanctot K.L., Paes B. The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence. J Med Econ 2013, 16(1):115-124.
42. Resch B., Resch E., Muller W. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favour. Paediatric Respiratory Reviews 2013, 14(2):130-136.
43. Isaacs D. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus? The case against. Paediatric Respiratory Reviews 2013, 14(2):128-129.
44. Frogel M.P., et al. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 2010, 16(1):46-58.
45. Leader S., Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002, 21(7):629-632.
46. Paramore L.C., et al. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004, 22(5):275-284.
47. Smart K.A., Lanctot K.L., Paes B.A. The cost effectiveness of palivizumab: a systematic review of the evidence. J Med Econ 2010, 13(3):453-463.
48. Nair H., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375(9725):1545-1555.
49. Thompson W.W., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(2):179-186.
50. Falsey A.R., et al. Acute respiratory tract infection in daycare centers for older persons. J Am Geriatr Soc 1995, 43(1):30-36.
51. Falsey A.R., et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 1995, 172(2):389-394.
52. Sorvillo F.J., et al. An outbreak of respiratory syncytial virus pneumonia in a nursing home for the elderly. J Infect 1984, 9(3):252-256.
53. Nicholson K.G., et al. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 1997, 315(7115):1060-1064.
54. Byington C.L., et al. Respiratory syncytial virus-associated mortality in hospitalized infants and young children. Pediatrics 2015, 135. pe24-e31.
55. Piedimonte G. Contribution of neuroimmune mechanisms to airway inflammation and remodeling during and after respiratory syncytial virus infection. Pediatr Infect Dis J 2003, 22(2 Suppl):S66-S74. discussion S74-5.
56. Openshaw P.J.M., Dean G.S., Culley F.J. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatric Infectious Disease Journal 2003, 22(2):S58-S65.
57. Piedimonte G., Hegele R.G., Auais A. Persistent airway inflammation after resolution of respiratory syncytial virus infection in rats. Pediatr Res 2004, 55(4):657-665.
58. Auais A., et al. Immunomodulatory effects of sensory nerves during respiratory syncytial virus infection in rats. Am J Physiol Lung Cell Mol Physiol 2003, 285(1):L105-L113.
59. Wedde-Beer K., et al. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol 2002, 282(5):L1143-L1150.
60. King K.A., et al. Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am J Respir Cell Mol Biol 2001, 24(2):101-107.
61. Leon A., et al. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci U S A 1994, 91(9):3739-3743.
62. Aung S., Rutigliano J.A., Graham B.S. Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease. J Virol 2001, 75(20):9918-9924.
63. Legg J.P., et al. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2003, 168(6):633-639.
64. Renz H., Kerzel S., Nockher W.A. The role of neurotrophins in bronchial asthma: contribution of the pan-neurotrophin receptor p75. Prog Brain Res 2004, 146:325-333.
65. Braun A., et al. Neurotrophins: a link between airway inflammation and airway smooth muscle contractility in asthma?. Int Arch Allergy Immunol 1999, 118(2-4):163-165.
66. Micera A., et al. Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. Proc Natl Acad Sci U S A 2001, 98(11):6162-6167.
67. Lewin G.R., Barde Y.A. Physiology of the neurotrophins. Annu Rev Neurosci 1996, 19:289-317.
68. Cohen S., Levi-Montalcini R., Hamburger V. A Nerve Growth-Stimulating Factor Isolated from Sarcom as 37 and 180. Proc Natl Acad Sci U S A 1954, 40(10):1014-1018.
69. Chao M.V., Rajagopal R., Lee F.S. Neurotrophin signalling in health and disease. Clin Sci (Lond) 2006, 110(2):167-173.
70. Zampieri N., Chao M.V. Mechanisms of neurotrophin receptor signalling. Biochem Soc Trans 2006, 34(Pt 4):607-611.
71. Reichardt L.F. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006, 361(1473):1545-1564.
72. Skaper S.D. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 2008, 7(1):46-62.
73. Ricci A., et al. Neurotrophin and neurotrophin receptor protein expression in the human lung. Am J Respir Cell Mol Biol 2004, 30(1):12-19.
74. Ricci A., et al. Increased pulmonary neurotrophin protein expression in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis 2007, 24(1):13-23.
75. Rochlitzer S., Nassenstein C., Braun A. The contribution of neurotrophins to the pathogenesis of allergic asthma. Biochem Soc Trans 2006, 34(Pt 4):594-599.
76. Hahn C., et al. Airway epithelial cells produce neurotrophins and promote the survival of eosinophils during allergic airway inflammation. J Allergy Clin Immunol 2006, 117(4):787-794.
77. Nockher W.A., Renz H. Neurotrophins and asthma: novel insight into neuroimmune interaction. J Allergy Clin Immunol 2006, 117(1):67-71.
78. Nockher W.A., Renz H. Neurotrophins in allergic diseases: from neuronal growth factors to intercellular signaling molecules. J Allergy Clin Immunol 2006, 117(3):583-589.
79. Kobayashi H., et al. Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimuli. Blood 2002, 99(6):2214-2220.
80. Noga O., et al. The production, storage and release of the neurotrophins nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 by human peripheral eosinophils in allergics and non-allergics. Clin Exp Allergy 2003, 33(5):649-654.
81. Santambrogio L., et al. Nerve growth factor production by lymphocytes. J Immunol 1994, 153(10):4488-4495.
82. Noga O., et al. Selective induction of nerve growth factor and brain-derived neurotrophic factor by LPS and allergen in dendritic cells. Clin Exp Allergy 2008, 38(3):473-479.
83. Raap U., et al. Modulation of neurotrophin and neurotrophin receptor expression in nasal mucosa after nasal allergen provocation in allergic rhinitis. Allergy 2008, 63(4):468-475.
84. Mohtasham L., Auais A., Piedimonte G. Nerve growth factor mediates steroid- resistant inflammation in respiratory syncytial virus infection. Pediatr Pulmonol 2007, 42(6):496-504.
85. Yao Q., et al. Hyperoxia enhances brain-derived neurotrophic factor and tyrosine kinase B receptor expression in peribronchial smooth muscle of neonatal rats. Am J Physiol Lung Cell Mol Physiol 2005, 289(2):L307-L314.
86. Yao Q., et al. Neonatal lung and airway injury: a role for neurotrophins. Semin Perinatol 2006, 30(3):156-162.
87. Bonini S., et al. Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma. Proc Natl Acad Sci USA 1996, 93:10955-10960.
88. Olgart Hoglund C., et al. Nerve growth factor levels and localisation in human asthmatic bronchi. Eur Respir J 2002, 20:1110-1116.
89. Virchow J.C., et al. Neurotrophins are increased in bronchoalveolar lavage fluid after segmental allergen provocation. Am J Respir Crit Care Med 1998, 158(6):2002-2005.
90. Dagnell C., et al. Increased levels of nerve growth factor in the airways of patients with sarcoidosis. J Intern Med 2008, 264(5):463-471.
91. Ricci A., et al. Neurotrophins and neurotrophin receptors in human lung cancer. Am J Respir Cell Mol Biol 2001, 25(4):439-446.
92. Rezaee F., et al. Respiratory syncytial virus infection in human bone marrow stromal cells. Am J Respir Cell Mol Biol 2011, 45(2):277-286.
93. Rohwedder A., et al. Detection of respiratory syncytial virus RNA in blood of neonates by polymerase chain reaction. J Med Virol 1998, 54(4):320-327.
94. Torres J.P., et al. Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice. Respir Res 2010, 11:p125.
95. Yui I., et al. Detection of human respiratory syncytial virus sequences in peripheral blood mononuclear cells. J Med Virol 2003, 70(3):481-489.
96. Menchise A. Myocarditis in the setting of RSV bronchiolitis. Fetal Pediatr Pathol 2011, 30(1):64-68.
97. Li X.Q., et al. Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein. J Virol 2006, 80(1):537-540.
98. Graham B.S., Johnson T.R., Peebles R.S. Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 2000, 48(3):237-247.
99. Kirin B.K., Topic R.Z., Dodig S. Hepatitis during respiratory syncytial virus infection--a case report. Biochem Med (Zagreb) 2013, 23(1):112-116.
100. Sweetman L.L., et al. Neurologic complications associated with respiratory syncytial virus. Pediatr Neurol 2005, 32(5):307-310.
101. Esposito S., et al. Altered cardiac rhythm in infants with bronchiolitis and respiratory syncytial virus infection. BMC Infect Dis 2010, 10:p305.
102. Das B., et al. CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med 2013, 5(170). p. 170ra13.
103. Piedimonte G. Respiratory syncytial virus and asthma: speed-dating or long-term relationship?. Curr Opin Pediatr 2013, 25(3):344-349.
104. Bueno S.M., et al. Host immunity during RSV pathogenesis. Int Immunopharmacol 2008, 8(10):1320-1329.
105. Lay M.K., et al. Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response. Microbes Infect 2013, 15(3):230-242.
106. Avendano L.F., Palomino M.A., Larranaga C. Surveillance for respiratory syncytial virus in infants hospitalized for acute lower respiratory infection in Chile (1989 to 2000). J Clin Microbiol 2003, 41(10):4879-4882.
107. Varga S.M., et al. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity 2001, 15(4):637-646.
108. Wan Y.Y., Flavell R.A. How Diverse-CD4 Effector T Cells and their Functions. Journal of Molecular Cell Biology 2009, 1(1):20-36.
109. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review. Virus Genes 2006, 33(2):235-252.
110. Lee H.C., et al. Thymic stromal lymphopoietin is induced by respiratory syncytial virus- infected airway epithelial cells and promotes a type 2 response to infection. J Allergy Clin Immunol 2012, 130(5). p. 1187-1196 e5.
111. Gut W., et al. RSV respiratory infection in children under 5 y.o.-dynamics of the immune response Th1/Th2 and IgE. Przegl Epidemiol 2013, 67(1):17-22. 105-9.
112. Olson M.R., Hartwig S.M., Varga S.M. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J Immunol 2008, 181(11):7958-7968.
113. Munir S., et al. Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response. PLoS Pathog 2011, 7(4):pe1001336.
114. Gonzalez P.A., et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc Natl Acad Sci U S A 2008, 105(39):14999-15004.
115. Gonzalez P.A., et al. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis. Curr Med Chem 2009, 16(34):4609-4625.
116. Singleton R., et al. Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses. J Virol 2003, 77(21):11303-11311.
117. Vallbracht S., Unsold H., Ehl S. Functional impairment of cytotoxic T cells in the lung airways following respiratory virus infections. Eur J Immunol 2006, 36(6):1434-1442.
118. Bueno S.M., et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci U S A 2008, 105(52):20822-20827.
119. Gonzalez P.A., et al. Understanding respiratory syncytial virus infection to improve treatment and immunity. Curr Mol Med 2013, 13(7):1122-1139.
120. Whimbey E., et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995, 21(2):376-379.
121. Henderson F.W., et al. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979, 300(10):530-534.
122. Hall C.B., et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991, 163(4):693-698.
123. Glezen W.P., et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140(6):543-546.
124. Hall C.B., Long C.E., Schnabel K.C. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 2001, 33(6):792-796.
125. Glezen W.P., et al. Risk of respiratory syncytial virus infection for infants from low- income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981, 98(5):708-715.
126. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics, 1997; 99(1): p. 93-9.
127. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics. Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics, 1998. 102(5): p. 1211-6.
128. Stensballe L.G., et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol 2009, 123(2):398-403.
129. Brand H.K., et al. CD4+ T-cell counts and interleukin-8 and CCL-5 plasma concentrations discriminate disease severity in children with RSV infection. Pediatr Res 2013, 73(2):187-193.
130. Bont L., et al. Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. J Infect Dis 2001, 184(3):355-358.
131. Kott K.S., et al. Effect of secondhand cigarette smoke, RSV bronchiolitis and parental asthma on urinary cysteinyl LTE4. Pediatr Pulmonol 2008, 43(8):760-766.
132. Mella C., et al. Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis 2013, 207(4):564-573.
133. Mandelberg A., et al. Lipopolysaccharide hyporesponsiveness as a risk factor for intensive care unit hospitalization in infants with respiratory syncitial virus bronchiolitis. Clin Exp Immunol 2006, 144(1):48-52.
134. Littel-van den Hurk S.V., Watkiss E.R. Pathogenesis of respiratory syncytial virus. Current Opinion in Virology 2012, 2(3):300-305.
135. Wedde-Beer K., et al. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol 2002, 282:L1143-L1150.
136. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003, 167:379-383.
137. Volovitz B., et al. The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. Pediatr Res 1988, 24(4):504-507.
138. van Schaik S.M., et al. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 1999, 103(4):630-636.
139. Piedimonte G., et al. Leukotriene synthesis during respiratory syncytial virus bronchiolitis: influence of age and atopy. Pediatr Pulmonol 2005, 40(4):285-291.
140. Sznajer Y., et al. Airway eicosanoids in acute severe respiratory syncytial virus bronchiolitis. J Pediatr 2004, 145:115-118.
141. Maclouf J., et al. Entry rate and metabolism of leukotriene C4 into vascular compartment in healthy subjects. Am J Physiol 1992, 263:H244-H249.
142. Huber M., et al. Metabolism of cysteinyl leukotrienes in monkey and man. Eur J Biochem 1990, 194:309-315.
143. Kumlin M., et al. Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans. Clin Exp Allergy 1995, 25:467-479.
144. Renzetti G., et al. Less air pollution leads to rapid reduction of airway inflammation and improved airway function in asthmatic children. Pediatrics 2009, 123(3):1051-1058.
145. Laham F.R., et al. LDH concentration in nasal-wash fluid as a biochemical predictor of bronchiolitis severity. Pediatrics 2010, 125(2):pe225-pe233.
146. Eisenhut M., Thorburn K. Hepatitis associated with severe respiratory syncytial virus-positive lower respiratory tract infection. Scand J Infect Dis 2002, 34(3):p235.
147. Eisenhut M. Extrapulmonary manifestations of severe RSV bronchiolitis. Lancet 2006, 368(9540):p988.
148. Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection--a systematic review. Crit Care 2006, 10(4):pR107.
149. Hanna S., et al. Incidence of hyponatraemia and hyponatraemic seizures in severe respiratory syncytial virus bronchiolitis. Acta Paediatr 2003, 92(4):430-434.
150. Houben M.L., et al. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. J Med Virol 2010, 82(7):1266-1271.
151. Borchers A.T., et al. Respiratory syncytial virus--a comprehensive review. Clin Rev Allergy Immunol 2013, 45(3):331-379.
152. DeVincenzo J.P. Factors predicting childhood respiratory syncytial virus severity: what they indicate about pathogenesis. Pediatr Infect Dis J 2005, 24(11 Suppl):S177-S183. discussion S182.
153. DeVincenzo J.P., El Saleeby C.M., Bush A.J. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 2005, 191(11):1861-1868.
154. Perkins S.M., et al. Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J Clin Microbiol 2005, 43(5):2356-2362.
155. Hon K.L., et al. Respiratory syncytial virus morbidity, premorbid factors, seasonality, and implications for prophylaxis. J Crit Care 2012, 27(5):464-468.
156. El Kholy A.A., et al. Morbidity and outcome of severe respiratory syncytial virus infection. Pediatr Int 2013, 55(3):283-288.
157. van den Kieboom C.H., et al. Nasopharyngeal gene expression, a novel approach to study the course of respiratory syncytial virus infection. Eur Respir J 2014.
158. Mejias A., et al. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med 2013, 10(11):pe1001549.